Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Appian Corp (APPN) vs Johnson & Johnson (JNJ) Price & Performance

Appian CorpTrade
Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

Appian Corp vs Johnson & Johnson — how do they compare? Appian Corp trades at $34.59 (market cap $2.54B), while Johnson & Johnson trades at $260.83 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 246.5× Appian Corp's market cap, and Johnson & Johnson pays a 2.06% dividend while Appian Corp pays none. Which is the better fit depends on your goals.

APPNJNJ
Market Cap
$2.54B$626.09B
Sector
TechnologyHealth
52-Week High
$45.64$267.24
52-Week Low
$18.72$172.78
Enterprise Value
$2.67B$654.37B
Volume
6,156,228
Dividend Yield
2.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Appian Corp

Appian Corporation (APPN) trades at $35.05, down 1.49% on the day, following a series of recent earnings beats. The stock exhibits a bullish technical trend with strong moving average support, though oscillators signal overbought conditions. Fundamentally, the company shows robust revenue growth, reaching $727 million in 2025, and has achieved positive net income after years of losses, yet maintains a negative shareholder equity position. Recent news highlights strategic AI partnerships and strong quarterly performance.

The outlook is cautiously optimistic, driven by AI-driven demand and enterprise growth, but significant risks persist, including high valuation multiples, negative equity, and intense competition. Analyst consensus is mixed, with a majority Hold rating, suggesting the stock may be fully valued near-term despite operational improvements.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.

Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Appian Corp

Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.

Read more on APPN

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ